Market Intelligence, Clinical Progress, and High-Purity Reagents for Adrenal Insufficiency and ACTH-Driven Endocrine Disorders.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MC2R drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MC2R ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. HEK293 Expressed. |
View MC2R Products |
| Gene Delivery | MC2R Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Native conformation preserved. |
View MC2R Products |
| Accessory Protein | MRAP (Melanocortin 2 Receptor Accessory Protein) Required for MC2R surface trafficking. Co-expression validated. |
View MRAP Products |
| Benchmark Ab/Peptide | Anti-MC2R / ACTH Analog Control Recombinant positive control for binding assays. |
View MC2R Products |
| Validator | MC2R siRNA Set For knockdown verification and specificity control. |
View MC2R Products |
| Related Target A | MC4R (Melanocortin-4 Receptor) Critical counter-screening target to avoid metabolic/weight side effects. |
View MC4R Products |
| Related Target B | MC1R (Melanocortin 1 Receptor) Skin pigmentation pathway; off-target screening essential. |
View MC1R Products |
Critical Assay Challenges & TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| MRAP-dependent Surface Trafficking | MRAP co-expression lentivirus available; HEK293 system preserves native interaction. Dual-promoter lentivirus encoding MC2R + MRAP available. |
| Complex Membrane Protein (GPCR) Expression | Lentivirus-based delivery for stable HEK293 cell lines; strictly avoids VLPs to ensure robust cellular context. Full-length ORF maintains native glycosylation. |
| Subfamily Selectivity (MC1R/MC3R/MC4R/MC5R) | Sequence Verified homolog panels available for rigorous selectivity profiling. Competitive binding assays using labeled ACTH analogs. |
| cAMP Signaling Validation | Sequence-verified ORF ensures functional Gs-coupling in reporter assays. Suitable for cAMP accumulation assays. |
| False Positives / Lack of Controls | Validated siRNA included for specificity checks. Clinical-grade reference antibodies and control peptides included. |
| GPCR Conformational Integrity | Full-length ORF lentivirus for cell-based assays; native membrane context maintained. |
Live MC2R R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MC2R therapeutics is intensifying, with major players shifting focus from traditional peptide analogs to small molecule antagonists. As an essential receptor for ACTH, MC2R is a prime target for congenital adrenal hyperplasia (CAH), Cushing's disease, and familial glucocorticoid deficiency (FGD). Unlike oncology targets, MC2R represents a precision endocrine opportunity. First-generation therapies (e.g., ACTH analogs, peptide antagonists) are approaching clinical proof-of-concept, while the next wave includes allosteric modulators and gene therapy. A key bottleneck is the absolute requirement of MRAP for functional surface expression; co-expression systems are essential for physiologically relevant assays.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Antagonist/Agonist) | Crinetics Pharmaceuticals, Neurocrine, Preclinical | CAH, Cushing's Disease | cAMP Accumulation Assay (Need MRAP + MC2R Lentivirus) |
| ACTH/Peptide Analogs | Diurnal, Crinetics, Various Biotechs | Adrenal Insufficiency, ACTH-related disorders | Cell Surface Expression & Receptor Binding (Requires MRAP co-transfection) |
| Monoclonal Antibodies | Early Discovery | Adrenal Hyperplasia | Epitope Mapping (Need high-purity extracellular loops) |
| Gene Therapy | Academic Consortia | FGD Type 1 | Stable Cell Line Generation (Lentivirus-based) |
| Biologics | Rare Disease Focus | ACTH Resistance | Binding Affinity (High-purity ECD-Fc required) |
Key Mutations and Functional Implications
Three clinically important mutations in MC2R are associated with familial glucocorticoid deficiency type 1 (GCCD1):
- rs28926178: Listed in dbSNP; documented in UniProt VAR_003509.
- rs104894658: Complete loss of activity; associated with GCCD1 (UniProt VAR_003510).
- rs768093045: Associated with GCCD1 (UniProt VAR_010702).
These loss-of-function mutations underscore the need for mutant-specific assays and patient-mutation matched reagents in drug development.
Related Targets for Cross-sell
- MRAP – Essential accessory protein; co-expression vectors and lentivirus available.
- MC4R – Off-target safety screening for metabolic effects.
- MC1R – Off-target screening for pigmentation effects.
- MC3R, MC5R – Additional melanocortin family members for comprehensive selectivity panels.